Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05137418 | Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years | PHASE3 | COMPLETED | 1,000 | — | — | Nov 27, 2021 | Jan 27, 2023 | Oct 16, 2023 | 1 | China |
The GMT of neutralizing antibodies 28 days after the second vaccination.
| Arm | Type | Description |
|---|---|---|
| 3-5 years old age group | EXPERIMENTAL | 500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28. |
| 6-11 years old age group | EXPERIMENTAL | 500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28. |
| Name | Type | Description |
|---|---|---|
| COVID-19 Vaccine,Inactivated | BIOLOGICAL | The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection |
Inclusion Criteria: * Healthy participants aged 3-11 years; * The participants and/or their guardians are able to understand and sign the informed consent voluntarily (in accordance with the local regulations)(For subjects aged 3-7years ,guardians need to sign the informed consent form,for subjects...